First AD

Second AD

Maintenance therapy for the treatment of patients with non-small cell lung cancer (NSCLC) has evolved in recent years. This treatment strategy has demonstrated improvements in overall survival and progression-free survival. Both switch and continuation strategies have demonstrated value, with a number of clinical trials showing impressive findings. In this discussion, panelists discuss various clinical trials exploring maintenance therapy in NSCLC. View the video, to learn more.

Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Special Reports in Personalized Cancer Care

The OncLive Special Reports in Personalized Cancer Care condition center is a comprehensive resource for clinical news and expert insights on personalized  treatment in lung cancer, breast cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, gynecologic cancers, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research as it relates to precision oncology therapeutics. 

Immunotherapy in Lung Cancer

The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.

Unmet Needs in the Treatment of Lung Cancer

Peer Exchange

Maintenance Therapy Clinical Trials for NSCLC

Introduction: Exploration of Nab-Paclitaxel in NSCLC

Nab-Paclitaxel in Non-Small Cell Lung Cancer

Maintenance Nab-Paclitaxel in Squamous NSCLC

Subgroup Analyses for Nab-Paclitaxel in NSCLC

Next-Generation EGFR Inhibitors in NSCLC

AZD9291 and Rociletinib in T790M-Mutant NSCLC

Afatinib Plus Cetuximab in Resistant NSCLC

Frontline ALK, EGFR Inhibition in NSCLC

Next-Generation ALK Inhibitors in NSCLC

Utilizing Next-Generation ALK Inhibitors in NSCLC

Efficacy of Next-Generation ALK Inhibitors

PD-1 Inhibition in Lung Cancer

Nivolumab in Non-Small Cell Lung Cancer

Multiple PD-1/PD-L1 Agents in Lung Cancer

PD-1/PD-L1 Inhibitors Across NSCLC Treatment Settings

Role of Maintenance Therapy in NSCLC

PointBreak and AVAPERL Studies in NSCLC

Emerging Therapies in Non-Small Cell Lung Cancer

Novel Angiogenesis Inhibitors in NSCLC

Potential New Biomarkers in Lung Cancer

Conclusion: Addressing Unmet Needs in Lung Cancer